Table 3 Clinical outcomes during follow-up periods according to resolution of AOI
Variables | Resolution (n = 36) | No resolution (n = 26) | p value |
|---|---|---|---|
Maximal extent, no. (%) | 0.656 | ||
Proctitis, no. (%) | 12 (33.3) | 9 (34.6) | Â |
Left-sided colitis, no. (%) | 14 (38.9) | 7 (26.9) | Â |
Extensive colitis, no. (%) | 10 (27.8) | 10 (38.5) | Â |
Proximal extension, no. (%) | 9 (25.0) | 8 (30.8) | 0.774 |
Mayo endoscopic score at the last endoscopy | 0.177 | ||
0–1, no. (%) | 32 (88.9) | 19 (73.1) |  |
2–3, no. (%) | 4 (10.8) | 7 (26.9) |  |
Histories of medications | |||
High dose 5-ASA, no (%) | 3 (8.3) | 4 (15.4) | 0.439 |
Corticosteroid, no. (%) | 21 (58.3) | 16 (61.5) | 1.000 |
Azathioprine/6-MP, no. (%) | 10 (27.8) | 10 (38.5) | 0.419 |
Anti-TNF agents, no. (%) | 0 (0.0) | 0 (0.0) | Â |
Colectomy, no. (%) | 0 (0.0) | 0 (0.0) | Â |
UC-related hospitalization, no. (%) | 7 (19.4) | 9 (34.6) | 0.242 |
Relapse during follow-up periods, no. (%) | 18 (50.0) | 13 (50.0) | 1.000 |
Follow-up duration, months, median (range) | 83 (1-185) | 84 (12–168) | 0.272 |